Corient Private Wealth’s Ascendis Pharma A/S ASND Stock Holding History

Corient Private Wealth’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	3,768 +385	+11%	+$89.9K	﹤0.01%	1814
2026 Q1	$774K	Sell	3,383 -10	-0.3%	-$2.24K	﹤0.01%	1789
2025 Q4	$724K	Buy	3,393 +510	+18%	+$105K	﹤0.01%	1669
2025 Q3	$573K	Hold	2,883	–	–	﹤0.01%	1721
2025 Q2	$498K	Sell	2,883 -511	-15%	-$83.2K	﹤0.01%	1706
2025 Q1	$529K	Buy	3,394 +123	+4%	+$17.6K	﹤0.01%	1571
2024 Q4	$450K	Buy	+3,271	New	+$430K	﹤0.01%	1679

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Corient Private Wealth's ASND Position: Q2 2026 in Review

Corient Private Wealth increased its Ascendis Pharma A/S (ASND) stake by 11% in Q2 2026, buying an estimated $89.9K and bringing the position to 3,768 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Corient Private Wealth first reported a position in ASND in Q4 2024 and has held it in 7 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Corient Private Wealth held 3,768 shares of Ascendis Pharma A/S worth $1.01M as of Q2 2026.
Corient Private Wealth bought 385 Ascendis Pharma A/S shares in Q2 2026, an estimated $89.9K.
Ascendis Pharma A/S made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1814 holding.
Corient Private Wealth first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 7 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.